Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Atlas Venture, Inc. Address: 890 Winter Street Suite 320 Waltham, MA 02451 UNITED STATES Map It Contact Info: T: (781) 622-1700 F: (781) 622-1701 E: [email protected] Website URL: www.atlasventure.com/ Other Locations 1201 Third Avenue Suite 5450 Seattle, WA 98101, USA t: +1 206 694 8600 f: +1 206 254 9130 e: [email protected] Go Back About Us Atlas Venture is the leading international early-stage venture capital firm, investing in communications, information technology and life sciences companies. Atlas Venture has investing offices in Boston, London, Menlo Park, Munich, Paris and Seattle, and its investments are evenly divided between the United States and Europe. Founded in 1980, Atlas Venture has organized six international funds, and currently manages more than $2.4 billion in committed capital. The Life Sciences investment team offers portfolio companies expertise in biotechnology licensing and marketing, business management, and medical practice. Preferred Stage Many of Atlas Venture’s Life Sciences portfolio companies are developing new platform technologies to leverage the data generated from the human genome project and enhance the drug discovery process. Others are developing new medical devices, or using the Internet to streamline drug development and healthcare delivery. Geographic Focus With more than twenty years in international venture investing, the Atlas Venture team has developed a vast international network of business contacts to help portfolio companies make connections quickly. With offices and local contacts in major American and European markets, can provide practical assistance to companies expanding operations to other countries. Capital More than $2.4 billion in committed capital Investment Portfolio Acambis Plc, Achillion Pharmaceuticals, Inc, Actelion Pharmaceuticals Ltd, Akceli, Inc, Allelix Biopharmaceuticals Inc, Alnylam Pharmaceuticals, Inc., Anadys Pharmaceuticals, Archemix Corp, ArQule, Inc, Artemis Pharmaceuticals GmbH, Aureon Biosciences, Axovan Ltd., Boston Medical Technologies, Inc CellZome GmbH, Ciphergen Biosystems, Inc, CropDesign NV, Crucell NV, deCODE genetics, Inc, DeveloGen AG, EntoMed SA, Exelixis, Inc, Hexagen Plc, Immuno-Designed Molecules SA, IsoTis NV, Kriton Medical, MediGene AG, Microcide, Inc, Micromet AG, Modex Therapeutiques SA, MorphoSys AG, Neurochem, Inc, Neurotech SA, Newron Pharmaceuticals, Novuspharma S.p.A., NxStage Medical, Oxford GlycoSciences Plc, Percardia Inc, Prolifix Ltd, Renovo, Ltd, Signature BioScience, Inc, Structural GenomiX, Inc, Transfusion Technologies, Inc, Variagenics, Inc, Vasca, Inc Investor Cross Search Click on the company name to see other investors in the company. Acambis, Achillion Pharmaceuticals, Actelion Pharmaceuticals, Akceli, Allelix Biopharmaceuticals, Alnylam Pharmaceuticals, Anadys Pharmaceuticals, Archemix, ArQule, Artemis Pharmaceuticals, Aureon Biosciences, Axovan, Boston Medical Technologies, CellZome, Ciphergen Biosystems, CropDesign, Crucell deCODE genetics DeveloGen EntoMed Exelixis Hexagen, Immuno-Designed Molecules, IsoTis, Kriton Medical, MediGene, Microcide, Micromet, Modex Therapeutiques, MorphoSys, Neurochem, Neurotech, Newron Pharmaceuticals, Novuspharma, NxStage Medical, Oxford GlycoSciences, Percardia, Prolifix, Renovo, Signature BioScience, Structural GenomiX, Transfusion Technologies, Variagenics, Vasca